Minerva Neurosciences Inc. (NASDAQ:NERV)’s share price was up 4% on Wednesday . The company traded as high as $10.85 and last traded at $10.55, with a volume of 156,494 shares. The stock had previously closed at $10.14.

A number of equities analysts have weighed in on NERV shares. JMP Securities upped their price target on Minerva Neurosciences from $10.00 to $17.00 in a research report on Thursday, May 26th. Jefferies Group reissued a “buy” rating and issued a $17.00 price objective (up previously from $10.00) on shares of Minerva Neurosciences in a report on Friday, May 27th. Finally, Zacks Investment Research downgraded Minerva Neurosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 20th.

The company’s market capitalization is $295.35 million. The company’s 50 day moving average is $9.65 and its 200-day moving average is $6.68.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.04. On average, analysts forecast that Minerva Neurosciences Inc. will post ($1.05) earnings per share for the current year.

In other Minerva Neurosciences news, Director David Kupfer bought 55,635 shares of the stock in a transaction on Tuesday, June 21st. The stock was acquired at an average cost of $10.84 per share, for a total transaction of $603,083.40. Following the completion of the acquisition, the director now owns 209,188 shares in the company, valued at approximately $2,267,597.92. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.